Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Opthea Limited ( (AU:OPT) ) has shared an update.
Opthea Limited announced the progress of its lead product, sozinibercept, in pivotal Phase 3 trials for wet AMD, showcasing its potential to improve visual acuity when used alongside standard treatments. The company highlighted promising results from previous trials, strategic leadership enhancements, and a significant R&D Tax Incentive, which bolster its market positioning and potential impact on stakeholders.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing new therapies for retinal diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s main product candidate, sozinibercept, is currently under evaluation in Phase 3 clinical trials and aims to enhance visual outcomes in combination with anti-VEGF-A therapies.
YTD Price Performance: 9.09%
Average Trading Volume: 9,900
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $791.1M
See more data about OPT stock on TipRanks’ Stock Analysis page.
